Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Stryker Co. (NYSE:SYK - Get Rating) has received an average recommendation of "Moderate Buy" from the nineteen brokerages that are presently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $256.00.

Several equities analysts have recently commented on SYK shares. Robert W. Baird reduced their price objective on Stryker from $297.00 to $240.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 27th. Truist Financial increased their target price on shares of Stryker to $220.00 and gave the company an "outperform" rating in a report on Wednesday, July 27th. Deutsche Bank Aktiengesellschaft lowered shares of Stryker from a "buy" rating to a "hold" rating and cut their price target for the company from $285.00 to $205.00 in a research report on Thursday, July 21st. StockNews.com upgraded Stryker from a "hold" rating to a "buy" rating in a report on Monday, August 15th. Finally, BTIG Research dropped their target price on Stryker from $278.00 to $244.00 and set a "buy" rating for the company in a report on Monday, July 18th.Stryker Stock Down 0.0 %

Shares of NYSE SYK opened at $205.20 on Thursday. The company has a current ratio of 2.00, a quick ratio of 1.15 and a debt-to-equity ratio of 0.85. The business has a 50-day moving average of $207.53 and a 200-day moving average of $232.66. The firm has a market capitalization of $77.60 billion, a price-to-earnings ratio of 37.79, a PEG ratio of 2.51 and a beta of 1.03. Stryker has a 12 month low of $188.84 and a 12 month high of $281.16.

Stryker (NYSE:SYK - Get Rating) last issued its quarterly earnings results on Tuesday, July 26th. The medical technology company reported $2.25 EPS for the quarter, missing analysts' consensus estimates of $2.28 by ($0.03). Stryker had a return on equity of 23.34% and a net margin of 11.79%. During the same quarter in the prior year, the business posted $2.25 earnings per share. Sell-side analysts expect that Stryker will post 9.38 earnings per share for the current fiscal year. Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be given a $0.695 dividend. This represents a $2.78 annualized dividend and a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, September 29th. Stryker's dividend payout ratio is currently 51.20%. Institutional Investors Weigh In On Stryker

Several hedge funds have recently made changes to their positions in the company. LGT Group Foundation increased its position in Stryker by 307.9% during the 1st quarter. LGT Group Foundation now owns 7,101 shares of the medical technology company's stock valued at $1,910,000 after buying an additional 5,360 shares in the last quarter. Compass Financial Advisors LLC purchased a new stake in shares of Stryker in the fourth quarter worth $562,000. Spears Abacus Advisors LLC boosted its stake in Stryker by 31.9% in the 4th quarter. Spears Abacus Advisors LLC now owns 2,511 shares of the medical technology company's stock worth $671,000 after purchasing an additional 608 shares in the last quarter. Retirement Group LLC grew its position in Stryker by 86.8% during the 4th quarter. Retirement Group LLC now owns 99 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. Finally, Peak Asset Management LLC increased its stake in Stryker by 0.6% during the 1st quarter. Peak Asset Management LLC now owns 54,321 shares of the medical technology company's stock valued at $14,523,000 after purchasing an additional 345 shares in the last quarter. 76.44% of the stock is currently owned by institutional investors. Stryker Company Profile (Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.Further ReadingGet a free copy of the StockNews.com research report on Stryker (SYK)Can Alibaba And Baidu Finally Rally With Delisting Fears Gone? Is World Wresting Entertainment Getting Ready to Be Sold? 3 Materials Stocks That May Earn a Place on Your Watchlist Crowdstrike Stock Retraces, As Earnings Sober ExpectationsWill The Institutions Buy The Dip In Ambarella Stock? 

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Tom remains optimistic about investors’ prospects going forward, even as the market reacts to the words of Fed Chair Jerome Powell about “pain ahead.”

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.